Future research aims to develop more selective and potent CDK inhibitors with fewer side effects. Understanding the structural biology of CDKs and their complexes with cyclins and inhibitors can aid in the rational design of new drugs. Additionally, exploring the role of CDKs in non-cancerous diseases can open new therapeutic avenues.